Disodium pamidronate

I Brand Name(s) Aredia, Pamidronate Disodium Novaplus Chemical Class Pyrophosphate analog... 

Bisphosphonates alendronate sodium clodronate disodium etidronate disodium pamidronate disodium risedronate sodium zoledronic acid... 

Adverse effects with various forms of pamidronate included 23 cases of suspected ocular adverse drug reactions associated with the use of intravenous pamidronate disodium (21). Bilateral anterior uveitis occurred 24-48 hours after administration in six cases three reports involved unilateral episcleritis, occurring 1-6 days after administration and 13 patients complained of non-specific transient conjunctivitis 6-8 hours after administration. 

Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994 118(2) 220-4. 

Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999 80(9) 998-1000. 

Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SRTauer K, Neidhart J, Mallette LE, Siegel R, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992 10 ... 

Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R, Navari R, Ahmann F, Zelenakas K, Heffernan M, Knight RD.Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994 154 1935-1944. 

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, et al. Longterm efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial. Cancer 2003 98 1735-1 744. 

Berenson JR, Rosen L, Vescio R, Lau FIS, Woo M, SloufI A, Kowalski MO, Knight RD, Seaman JJ. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997 37 285-290. 

Clinically, the animals do not show signs until 24-48 or more hours after ingestion of the bait. The affected animals are depressed, have reduced urine production, and the urine is of low specific gravity. Severely poisoned animals have hematemesis, azotemia, and cardiac arrhythmias. Animals with renal impairment are more susceptible to cholecalciferol poisoning than those with normal renal function. Cholecalciferol poisoning requires protracted treatment, which may require as long as 3 weeks in severe intoxications. Appropriate treatment consists of fluid therapy to assist the kidneys in removing the excess calcium, corticosteroids to minimize inflammation, and calcitonin to enhance calcium resorption into the bone. Pamidronate disodium is the new antidote for this poison. 

Pamidronate disodium is a bisphosphonate that inhibits normal and abnormal bone resorption. It is indicated in the treatment of moderate to severe hypercalcemia associated... 

Journal of Microencapsulation 20, No.4, July-Aug.2003, p.509-24 MICROENCAPSULATION OF HYDROPHILIC DRUG SUBSTANCES USING BIODEGRADABLE POLYESTERS. PART 1 EVALUATION OF DIFFERENT TECHNIQUES FOR THE ENCAPSULATION OF PAMIDRONATE DISODIUM SALT... 

Aredia, pamidronate disodium (APD), is a bone-resorption inhibitor used to treat hypercalcemia associated with malignancy and osteolytic bone lesions associated with multiple myeloma, metastatic breast cancer, and moderate to severe Paget s disease of bone. Aredia, a member of the group of chemical compounds known as bisphosphonates, is an analog of pyrophosphate. Pamidronate disodium is designated chemically as phosphonic acid (3-amino-l-hydroxypropylidene) bis-, disodium salt, pentahydrate, (APD). 

Pamidronate disodium is a white powder with inactive ingredients mannitol, USP, and phosphoric acid (for adjustment to pH 6.5 prior to lyophiliza-tion). 

Pamidronate disodium is a bisphosphonate which binds irreversibly to hydroxyapatite in bone. It is a strong inhibitor of bone resorption, reducing osteoclast or osteoclast precursor activity. Bisphosphonates inhibit bone resorption by selective adsorption to mineral surfaces and subsequent internalization by bone-resorbing osteoclasts. 

Vials - 30 mg - each contains 30 mg of sterile, lyophilized pamidronate disodium and 470 mg of mannitol, USP... 

---